Company Overview of Bayer Pharma AG
Bayer Pharma AG develops drugs and therapeutics for cardiovascular and blood diseases, oncological diseases, ophthalmology, and women's health. It offers prescription medicines for cardiovascular and blood diseases that include heart attack, high blood pressure, peripheral arterial occlusive disease, pulmonary hypertension, stroke, and thrombosis; oncological diseases, such as breast cancer, liver cancer, non-Hodgkin lymphoma, prostate cancer, and renal cell cancer; and ophthalmology diseases, including age-related macular degeneration. The company also offers prescription medicines for hormonal contraception, endometriosis, gynecological diseases, menopausal complaints, and premenstrual dys...
Founded in 1851
Key Executives for Bayer Pharma AG
Chief Executive Officer and Chairman of Management Board
Chief Financial Officer and Member of Management Board
Head of Specialized Therapeutics Business Area
Head of Latin American Canada Region Operations
Compensation as of Fiscal Year 2014.
Bayer Pharma AG Key Developments
OncoMed Pharmaceuticals, Inc. Announces Selection of First Small Molecule Product Under Collaboration With Bayer Pharma AG
Sep 30 14
OncoMed Pharmaceuticals, Inc. announced selection of first small molecule product candidate targeting the Wnt pathway under collaboration with Bayer Pharma AG. The small molecule product candidate is advancing to preclinical development triggering a $2 million milestone payment to OncoMed. OncoMed and Bayer initiated joint discovery efforts to identify small molecule inhibitors of the Wnt pathway, a key cancer stem cell pathway, as part of the companies' collaboration initiated in 2010. This is the first small molecule inhibitor of a cancer stem cell pathway from the collaboration to enter preclinical development. Bayer will lead development and commercialization of Wnt small molecule product candidates.
Statute of Limitations Bars Claims Alleging Bayer Healthcare Pharmaceuticals Inc., Bayer Pharma AG and Bayer Healthcare Pharmaceuticals's IUD Perforated Patient's Uterus
Jul 25 14
Dismissing as time-barred claims arising from injuries a claimant suffered when an intrauterine device (IUD) migrated into her abdomen, the U.S. District Court for the Southern District of New York concluded that the statute of limitations began to run when the claimant should have been on notice of a possible connection between her injuries and the device. Bayer Healthcare Pharmaceuticals Inc., Bayer Pharma AG and Bayer Healthcare Pharmaceuticals (Bayer) manufactures Mirena, an IUD designed to prevent pregnancy for up to five years. On April 30, 2009, Dr. Cathy Carr inserted Mirena into a patient. In early July 2011, the patient began to experience nausea and vomiting. On July 7, 2011, Carr examined the patient and informed her the IUD may have moved. The patient went to the emergency room on July 8 and July 9, 2011. An examination revealed the IUD perforated the patient's uterus and migrated to her lower abdomen. The patient underwent emergency surgery to remove the IUD. She sued Bayer on Sept. 26, 2013. Bayer moved to dismiss on statute of limitations grounds. The district court observed that a two-year statute of limitations applied to the patient's defective design and manufacture, failure to warn and strict liability claims. The patient contended the statute of limitations did not begin to run until May 2013 when she saw a commercial that linked the injuries she suffered to Mirena. The district court disagreed. The statute of limitations for product liability claims accrues when a plaintiff knows or should know through the exercise of ordinary diligence that a product harmed her and she should inquire into her legal rights. By July 8 or 9, 2011, the patient knew she was injured and that the injury was in some way caused by Bayer's device. The patient, however, did not file suit until more than two years later so her products liability claims were untimely. The patient argued her suspicion that she was injured as a result of her doctor's negligence, as opposed to any negligence by Bayer, tolled the statute of limitations. The district court determined the existence of an alternative explanation for the patient's injuries did not mean the information the patient possessed on July 8 or 9, 2011, was insufficient to prompt her to investigate the device's role in causing her injuries.
arGEN-X Announces Collaboration with Bayer Pharma AG to Discover and Develop Therapeutic Antibody Candidates
May 28 14
arGEN-X announced the initiation of a collaboration with Bayer Pharma AG, leveraging arGEN-X's SIMPLE Antibody(TM) technology for the discovery and development of therapeutic antibodies. The collaboration centers on a novel approach to addressing complex targets across multiple therapeutic areas that are often intractable by existing antibody platforms. With this collaboration, arGEN-X will apply its SIMPLE Antibody(TM) technology to multiple targets submitted by Bayer. The parties will work together to validate human antibody leads in disease-relevant models, with Bayer being responsible for further preclinical and clinical development and commercialization of therapeutic antibody products. Under the terms of the Agreement, Bayer will pay arGEN-X an upfront technology access fee, research support and technical success-based milestones. Bayer will also pay clinical, regulatory and product sales-based milestones as antibody programs progress through clinical development and registration.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|